Evaluation of effectiveness of granulocyte-macrophage colony-stimulating factor therapy to cancer patients after chemotherapy: a meta-analysis.

about

Evaluation of effectiveness of granulocyte-macrophage colony-stimulating factor therapy to cancer patients after chemotherapy: a meta-analysis.

Item

http://www.wikidata.org/entity/Q55384404

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis.

@en

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis.

@nl

type

Item

label

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis.

@en

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis.

@nl

prefLabel

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis.

@en

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis.

@nl

P1476

Evaluation of effectiveness of ...... chemotherapy: a meta-analysis

@en

P2093

Wen-Liang Yu

http://www.w3.org/2001/XMLSchema#string

Zi-Chun Hua

http://www.w3.org/2001/XMLSchema#string

P2860

Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients

G-CSF and GM-CSF in Neutropenia

Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor

Granulocyte-macrophage colony-stimulating factor treatment before doxorubicin and cyclophosphamide chemotherapy priming in women with early-stage breast cancer.

Growth factor use in medication-induced hematologic toxicity.

Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.

Granulocyte-macrophage colony-stimulating factor: not just another haematopoietic growth factor.

Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.

The role of myelopoietic growth factors in managing cancer in the elderly.

Clinical use of subcutaneous G-CSF or GM-CSF in malignancy.

P304

28226-28239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24890

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29963274

http://www.w3.org/2001/XMLSchema#string

P932

6021338

http://www.w3.org/2001/XMLSchema#string